Cardio Diagnostics Holdings Inc CEO Meesha Dogan, Accepted into Forbes Technology Council

Rhea-AI Summary

Cardio Diagnostics (Nasdaq: CDIO) has been accepted into the Forbes Technology Council, an exclusive community for top technology executives. CEO Meesha Dogan, PhD, emphasized that the company's innovative approach combines epigenetics, genetics, high-throughput computing, and AI to enhance early detection and prevention of cardiovascular disease. This prestigious membership is based on Dr. Dogan's significant professional achievements and aims to further strengthen the company's impact in the cardiovascular health sector.

Positive

• Acceptance into Forbes Technology Council increases visibility and credibility.
• Membership may lead to networking opportunities with key industry leaders.

Negative

• None.

Forbes Technology Council Is an Invitation-Only Community for World-Class CIOs, CTOs, and Technology Executives.

CHICAGO--(BUSINESS WIRE)-- Meesha Dogan, PhD, the CEO of Cardio Diagnostics (Nasdaq: CDIO), a precision cardiovascular disease company, has been accepted into Forbes Technology Council, an invitation-only community for world-class CIOs, CTOs, and technology executives.

Cardio Diagnostics is a biotechnology company that makes cardiovascular disease prevention and early detection more accessible, personalized, and precise. The company’s scientific and clinical studies have shown that an approach, which combines the emerging science of epigenetics and genetics, high-throughput computing, and AI, can close the current gap in our ability to clinically and precisely identify those of us at risk for heart disease.

“With Cardio’s current and future solutions, we’ll continue to fuel a new wave of innovation in preventing and detecting heart disease that can change the projected trajectory. It is a story I’m proud we get to tell via key channels like Forbes,” said Dr. Dogan.

Meesha Dogan was vetted and selected by a review committee based on the depth and diversity of her experience. Criteria for acceptance include a track record of successfully impacting business growth metrics and personal and professional achievements and honors.

“We are honored to welcome Meesha Dogan into the community,” said Scott Gerber, founder of Forbes Councils, the collective that includes Forbes Technology Council. “Our mission with Forbes Councils is to bring together proven leaders from every industry, creating a curated, social capital-driven network that helps every member grow professionally and make an even greater impact on the business world.”

ABOUT FORBES COUNCILS

Forbes Councils is a collective of invitation-only communities created in partnership with Forbes and the expert community builders who founded the Young Entrepreneur Council (YEC). In Forbes Councils, exceptional business owners and leaders come together with the people and resources that can help them thrive.

For more information about Forbes Technology Council, visit forbestechcouncil.com. To learn more about Forbes Councils, visit forbescouncils.com.

About Cardio Diagnostics

Cardio Diagnostics is a biotechnology company that makes cardiovascular disease prevention and early detection more accessible, personalized, and precise. The Company was formed to further develop and commercialize a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine™ (“Core Technology”) for cardiovascular disease to become one of the leading medical technology companies for enabling improved prevention, early detection, and assists in the treatment of cardiovascular disease. For more information, please visit www.cardiodiagnosticsinc.com.

Forward-Looking Statements

This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "should," "believe," and similar expressions are intended to identify such forward-looking statements. Forward-looking statements include, without limitation, the Company’s expectations with respect to future performance, development and commercialization of products and services, the potential benefits and impact of the Company’s products and services, potential regulatory approvals, and the size and potential growth of current or future markets for the Company’s products and services. Forward-looking statements are statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties that could cause the actual results to differ materially from the expected results. These statements are based on various assumptions, whether or not identified in this press release, and are not intended to serve as, and they must not be relied on by an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Factors that may cause such differences include, but are not limited to: the success, cost and timing of the Company’s product development and commercialization activities, including the degree that Epi+Gen CHD™, Cardio’s initial test, is accepted and adopted by patients, healthcare professionals and participants in other key channels; the impact of COVID-19 on the Company’s business; the inability to maintain the listing of the Company’s common stock on Nasdaq; changes in applicable laws or regulations; the inability of the Company to raise financing in the future; the inability of the Company to obtain and maintain regulatory clearance or approval for its tests, and any related restrictions and limitations of any cleared or approved product; the inability of the Company to identify, in-license or acquire additional technology; the inability of the Company to maintain its existing or future license, manufacturing, supply and distribution agreements; the inability of the Company to compete with other companies currently marketing or engaged in the development of products and services that could serve the same or similar functions as the Company’s products and services; the size and growth potential of the markets for the Company’s products and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company’s products and services and reimbursement for medical tests conducted using the Company’s products and services; the Company’s estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the Company’s financial performance; and other risks and uncertainties indicated from time to time in the Company’s filings with the Securities and Exchange Commission. The Company cautions readers that the foregoing list of factors is not exclusive and cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does notundertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221114005401/en/

Investors:

Meesha Dogan, Ph.D.

CEO

855-226-9991

investors@cardiodiagnosticsinc.com

Media & Public Relations:

Khullani Abdullahi

pr@cardiodiagnosticsinc.com

Source: Cardio Diagnostics

FAQ

What does Cardio Diagnostics specialize in?

Cardio Diagnostics specializes in precision cardiovascular disease prevention and early detection.

Who is the CEO of Cardio Diagnostics?

The CEO of Cardio Diagnostics is Meesha Dogan, PhD.

What is the significance of Cardio Diagnostics' acceptance into the Forbes Technology Council?

Acceptance into the Forbes Technology Council enhances the company's credibility and may provide networking opportunities.

What is Nasdaq: CDIO?

Nasdaq: CDIO is the stock symbol for Cardio Diagnostics.